로그인
회원가입
Korean
Korean
English
Chinese
Japanese
Home
Introduction
Contact us
People
PI
Members
Research
Projects
Lab Facility
Publications
Papers
Books
Patents
Photo gallery
Photo gallery
Board
Projet update
Recruiting
Journal club
Home
People
Research
Publications
Photo gallery
Board
Home
Introduction
Contact us
People
PI
Members
Research
Projects
Lab Facility
Publications
Papers
Books
Patents
Photo gallery
Photo gallery
Board
Projet update
Recruiting
Journal club
MOON LAB SNS 바로가기
트위터
페이스북
네이버블로그
MOON LAB
홈페이지 바로가기
MOON LAB
Moon lab pursues development of novel therapeutics for breast, ovary, and prostate cancer
Journal club 글답변
이름
필수
비밀번호
필수
분류
선택하세요
Journal Club
Projet update
HTML
제목
필수
웹에디터 시작
> > > Date: 2021.05.25 > > Title: Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer > > Clin Cancer Res. 2016 Feb 1;22(3):644-56. doi: 10.1158/1078-0432.CCR-14-3081. Epub 2015 Jul 29. > > Abstract > Purpose: Oncogenic mutations in the KRAS/PI3K/AKT pathway are one of the most frequent alterations in cancer. Although PI3K or AKT inhibitors show promising results in clinical trials, drug resistance frequently emerges. We previously revealed Wnt/β-catenin signaling hyperactivation as responsible for such resistance in colorectal cancer. Here we investigate Wnt-mediated resistance in patients treated with PI3K or AKT inhibitors in clinical trials and evaluate the efficacy of a new Wnt/tankyrase inhibitor, NVP-TNKS656, to overcome such resistance. > > Experimental design: Colorectal cancer patient-derived sphere cultures and mouse tumor xenografts were treated with NVP-TNKS656, in combination with PI3K or AKT inhibitors.We analyzed progression-free survival of patients treated with different PI3K/AKT/mTOR inhibitors in correlation with Wnt/β-catenin pathway activation, oncogenic mutations, clinicopathological traits, and gene expression patterns in 40 colorectal cancer baseline tumors. > > Results: Combination with NVP-TNKS656 promoted apoptosis in PI3K or AKT inhibitor-resistant cells with high nuclear β-catenin content. High FOXO3A activity conferred sensitivity to NVP-TNKS656 treatment. Thirteen of 40 patients presented high nuclear β-catenin content and progressed earlier upon PI3K/AKT/mTOR inhibition. Nuclear β-catenin levels predicted drug response, whereas clinicopathologic traits, gene expression profiles, or frequent mutations (KRAS, TP53, or PIK3CA) did not. > > Conclusions: High nuclear β-catenin content independently predicts resistance to PI3K and AKT inhibitors. Combined treatment with a Wnt/tankyrase inhibitor reduces nuclear β-catenin, reverts such resistance, and represses tumor growth. FOXO3A content and activity predicts response to Wnt/β-catenin inhibition and together with β-catenin may be predictive biomarkers of drug response providing a rationale to stratify colorectal cancer patients to be treated with PI3K/AKT/mTOR and Wnt/β-catenin inhibitors. > >
웹 에디터 끝
첨부파일
파일추가
파일삭제
자동등록방지
숫자음성듣기
새로고침
자동등록방지 숫자를 순서대로 입력하세요.
작성완료
취소
전화걸기
문자상담
PL
MEMBERS